Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368263 · ClinicalTrials.gov registry record · Phase 2
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01368263 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 8 participants.
The verdict
NCT01368263, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase II trial studies the impact of a presurgical endocrine therapy, consisting of goserelin with letrozole or anastrozole on the treatment of premenopausal patients with stage II-III estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Endocrine therapy reduces the amount of estrogen in the body. E+ breast cancer require estrogen, so lower levels of estrogen may slow or stop cell growth. Giving goserelin together with letrozole or anastrozole before surgery may enhance the effectiveness of, or eliminate the need for, chemotherapy
Interventions
- PROCEDURE Surgery
- DRUG letrozole
- DRUG anastrozole
- DRUG goserelin acetate
- DRUG chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01368263
The ClinicalTrials.gov registry entry for NCT01368263 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Surgery is the first listed.
NCT01368263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01368263 about?
NCT01368263 is a clinical study titled "Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer". This phase II trial studies the impact of a presurgical endocrine therapy, consisting of goserelin with letrozole or anastrozole on the treatment of premenopausal patients with stage II-III estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. E...
What is the current status of trial NCT01368263?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2011-09. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01368263?
The interventions under investigation include: Surgery (PROCEDURE), letrozole (DRUG), anastrozole (DRUG), goserelin acetate (DRUG), chemotherapy (DRUG).
Who is sponsoring clinical trial NCT01368263?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.